Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q1 FY2014 Earnings Presentation
18 slides from Torrent Pharmaceuticals's earnings presentation, 2013
Slide 1: Investor Presentation Q1 FY 2013-14
TORRENT PHARMACEUTICALS LTD. Investor Presentation Q1 FY 2013-14
Slide 2: Caveat
Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre
Slide 3: Contents
Contents 1. Performance Highlights 2. Financials 3. Business Segments – India – International 4. Facilities – Expansion Plan
Slide 4: Q1 FY14 Highlights
Q1 FY14 Highlights • Revenues at ` 972 Cr vs. ` 767 Cr, growing at 27% • During the quarter Company received one time Patent Assignment income of ` 42 Cr, adjusting which revenue growth stood at 21% • Domestic revenue growth of 12% • International operations growing at 28% • Europe & US markets key
Slide 5: Financials
Financials Fx orer
Slide 6: Revenue Progression
Revenue Progression ` Cr Q1 Q1 Particulars 12-13 11-12 13 - 14 12 - 13 India 312 278 1024 909 Gwth % 12% 13% International 539 422 1834 1482 Gwth % 28% 24% Brazil 133 136 502 477 Europe 196 131 650 542 USA 113 79 355 216 ROW (Incl. Russia & CIS) 85 70 297 227 Contract Manufacturing 67 65 300 296 Gwt
Slide 7: P&L
P&L ` Cr Q1 Q1 Particulars 12-13 11-12 13 - 14 12 - 13 Revenues 972 767 3,212 2,696 COGS 304 220 926 863 % Revenues 31% 29% 29% 32% SG&A Spend 275 214 965 778 % Revenues 28% 28% 30% 29% Employee Cost 172 152 623 534 % Revenues 18% 20% 19% 20% EBITDA 221 181 698 522 % Revenues 23% 24% 22% 19% Forex G
Slide 8: Balance Sheet
Balance Sheet ` Cr Particulars 31-Mar-13 % 30-Jun-13 % ∆ EQUITY AND LIABILITIES Shareholders' Funds 1,422 69% 1,448 69% 26 Minority Interest 0 0% 0 0% 0 Non-current liabilities 651 31% 638 31% (13) TOTAL 2,073 100% 2,086 100% 13 ASSETS Net Fixed Assets 1,105 53% 1,167 56% 62 Loans & Advances 63 3% 7
Slide 9: Business Segments: India
Business Segments India Fx orer
Slide 10: India: Highlights & Growth Drivers
India Highlights & Growth Drivers ` Cr Q1 Q1 India 12-13 11 - 12 13 - 14 12 - 13 Revenues 312 278 1024 909 % Growth 12% 13% 9% • Q1 FY 14 Highlights • New DPCO 2013 policy notified. Price notification issued for 293 out of 348 drugs under NLEM in 5 phases • Covered market growth 8%, Torrent growth 9
Slide 11: Business Segments: International Operations
Business Segments International Operations
Slide 12: Brazil: Highlights & Growth Drivers
Brazil Highlights & Growth Drivers ` Cr Q1 Q1 Brazil 12-13 11-12 13 - 14 12 - 13 Revenues 133 136 502 477 % Growth -2% 5% 34% • Q1 FY 14 Highlights • Covered Market growth : 6%, Torrent growth : 6%, Internal growth: 7%, • Reai degrowth – 2% during the quarter mainly coming out of price reductions ta
Slide 13: USA: Highlights & Growth Drivers
USA Highlights & Growth Drivers ` Cr Q1 Q1 USA 12-13 11-12 13 - 14 12 - 13 Revenues 113 79 355 216 % Growth 43% 64% 89% • Q1 FY 14 Highlights • Revenue growth of 38% on constant currency basis • Adjusting for the one time outlicensing income received in last year Growth – 53%; Constant Currency 48%
Slide 14: Europe: Highlights & Growth Drivers
Europe Highlights & Growth Drivers ` Cr Q1 Q1 Europe 12-13 11-12 13 - 14 12 - 13 Revenues 196 131 650 542 % Growth 49% 20% 16% • Q1 FY 14 Highlights • Euro revenue growth of 43% • Heumann and Europe (Dossier business) major contributors to growth • Growth Drivers • New Products going off patent and
Slide 15: ROW incl. RCIS: Highlights & Growth Drivers
ROW inc RCIS Highlights & Growth Drivers ` Cr Q1 Q1 ROW+RCIS 12-13 11-12 13 - 14 12 - 13 Revenues 85 70 297 227 % Growth 23% 85% 16% • Q1 FY14 Highlights • Revenue growth of 15% on constant currency basis. • Growth Drivers • Middle East/ Africa Region Delivering the growth being an upcoming market •
Slide 16: Facilities – Expansion Plan
Facilities — Expansion Plan Fx orer
Slide 17: Facilities – Expansion Plan: Dahej SEZ
Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1100 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 750 crores, First Regulatory Approval: Q1’14-15 • Pha
Slide 18: Thank You
Thank You Fx orer
Torrent Pharmaceuticals — Q1 FY2014 Earnings Presentation on 6ix